Vium, Inc., a San Mateo, Calif.–based company leveraging a living informatics approach to accelerate preclinical drug discovery and development, closed a $24m Series B financing.
The round was led by existing investors Lux Capital and Data Collective (DCVC), with participation from Dolby Family Ventures, Founders Fund and Tony Fadell’s Future Shape LLC.
As part of the Series B financing, Lux Capital Co-founder & Managing Partner Peter Hebert and Data Collective (DCVC) Co-Founder and Co-Managing Partner Zachary Bogue joined the company’s Board of Directors.
Led by President and CEO Wendel Barr, Vium creates a living informatics platform for preclinical in vivo drug research. The Vium Digital VivariumTM, Vium Cloud, and online Research Suite allow scientists to optimize advances in bioengineered research models.
Customers run the spectrum of biotechnology, pharmaceutical and computational drug discovery companies, academia and novel therapeutic labs.
The solution is fully accredited by AAALAC International.